Ivosidenib Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Ivosidenib Therapy, 2025, version number 1a, viewed 26/03/2026, https://healthservice.hse.ie/documents/6654/901_v1a_Ivosidenib.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.	5

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (1)	IDH1 p.R132C	Cholangiocarcinoma	Ivosidenib
HSE (1)	IDH1 p.R132G	Cholangiocarcinoma	Ivosidenib
HSE (1)	IDH1 p.R132H	Cholangiocarcinoma	Ivosidenib
HSE (1)	IDH1 p.R132L	Cholangiocarcinoma	Ivosidenib
HSE (1)	IDH1 p.R132S	Cholangiocarcinoma	Ivosidenib